Abstract: The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

Abstract: An SOC estimation method includes calculate an electric quantity value of fixed step size for the mobile power supply, and then sequentially superimpose a unit electric quantity step by step to calculate an accumulated electric quantity from the last moment of SOC change, then compare the absolute value of the accumulated electric quantity with the electric quantity value of the fixed step size to determine whether the SOC value is added/subtracted the fixed step size or kept unchanged, and acquire an initial value of the accumulated electric quantity at the next moment. In above method, the division operation can be replaced by “if judgment” and addition/subtraction operations in actual programming, which greatly reduces the calculation amount for SOC estimation, thereby greatly reducing requirements for chip operational power and peripheral resources and equipment energy consumption, improving the speed and computing stability of SOC estimation.

Abstract: Methods, computer-readable storage media, and apparatuses for surfacing content items in a messaging system. The methods may include storing a content item generated by a client device of a user, the user associated with the messaging system and determining a score to assign to the interaction and updating a resurface score associated with the content item with the score. The methods may further include determining whether to resurface the content item to the user based on the resurface score and causing to be displayed on a display of the client device a user interface comprising a user interface item for the user to display the content item. The methods may further include updating weights used to determine the scores based on interactions of the user with the resurfaced content items.

Abstract: The present disclosure provides for multi-specific antibodies and antigen-binding fragments thereof that bind to human CLDN6 and CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the multi-specific antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.

Abstract: A heavy oil thermal recovery method based on a multi-composition thermal fluid in a supercritical state, comprising: injecting a mixing of steam and vacuum gas oil containing Fe(III) aromatic sulfonate dissolved therein into an subterranean formation to preheat the subterranean formation, and extracting light crude oil from the subterranean formation when a temperature of the subterranean formation reaches a required temperature for combustion of heavy oil; injecting the steam and a combustion-supporting gas into the subterranean formation to enable the heavy oil to be ignited and a temperature of the subterranean formation to be reached 600° C.; and injecting a multi-composition thermal fluid formed by mixing a hydrogen donor with water into the subterranean formation to enable the multi-composition thermal fluid to be heated to the supercritical state under heat provided by the combustion of the heavy oil, and extracting crude oil modified by the heavy oil through the multi-composition thermal fluid.

Abstract: A package structure including at least one semiconductor die and a redistribution structure is provided. The semiconductor die is laterally encapsulated by an encapsulant, and the redistribution structure is disposed on the semiconductor die and the encapsulant and electrically connected with the semiconductor die. The redistribution structure includes signal lines and a pair of repair lines. The signal lines include a pair of first signal lines located at a first level, and each first signal line of the pair of first signal lines has a break that split each first signal line into separate first and second fragments. The pair of repair lines is located above the pair of first signal lines and located right above the break. Opposite ending portions of each repair line are respectively connected with the first and second fragments with each repair line covering the break in each first signal line.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: This disclosure relates to LPA antagonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: In some implementations, a storage node receives data processing instructions from a compute node of a network architecture. The storage node detects a Directed Acyclic Graph (DAG) within the data processing instructions. The DAG includes a plurality of data processing operations arranged within the DAG according to an execution. The data processing operations further include user-defined function (UDF) information associated with a UDF. The storage node may retrieve a first data object from an object store of the distributed storage node based on object keys information within the plurality of data processing operations. The storage node may execute the plurality of data processing operations using the retrieved first data object to generate a DAG execution result, the executing of the plurality of data processing operations based on the execution order. The storage node may communicate the DAG execution result to the compute node in response to the data processing instructions.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The present disclosure provides LPA antagonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: The disclosure relates to technology for acceleration of GPUs in cloud. Instructions for a computational task are accessed. An allocation of data and instructions is calculated based on the data, the instructions, and dynamic GPU resources. The data and the instructions are provided to the GPUs in accordance with the allocation, which includes scheduling a set of instructions for parallel computation of an operation of the computational task on multiple sub-matrices of a data matrix. Separate portions of information are stored into corresponding different regions of non-transitory memory of a processor core to provide concurrent access to the multiple sub-matrices to the processor core. Each sub-matrix corresponds to a portion of the data matrix for which an operation of the computational task is to be performed. Each sub-matrix contains an element in the data matrix in common with another sub-matrix of the data matrix.

Abstract: This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.